Tag: inhibitors
RAAS Inhibitors and Risk of COVID-19
The authors concluded that RAAS inhibitors do not increase the risk of COVID-19 requiring admission to the hospital, including fatal cases and those admitted to intensive care units (ICUs), and should not be discontinued... read more
Expert Panel Develops NIH Treatment Guidelines for COVID-19
A panel of U.S. physicians, statisticians, and other experts has developed treatment guidelines for coronavirus disease 2019 (COVID-19). These guidelines, intended for healthcare providers, are based on published and preliminary... read more
Aldosterone Synthase in Peripheral Sensory Neurons Contributes to Mechanical Hypersensitivity during Local Inflammation in Rats
Local production of aldosterone by its processing enzyme aldosterone synthase within peripheral sensory neurons contributes to ongoing mechanical hypersensitivity during local inflammation via intrinsic activation of neuronal... read more
Correlation Among Endothelial Injury, Organ Dysfunction, and Several Biomarkers in Sepsis Patients
Protein C was superior for the prediction of organ dysfunction after 7 days of ICU treatment when compared with other biomarkers of endothelial function, inflammation, and coagulation. C-reactive protein (CRP) and white blood... read more
Potassium Homoeostasis and Pathophysiology of Hyperkalaemia
Since determination of potassium levels may be afflicted with various errors, potassium levels should be determined using a standardized set-up ensuring high accuracy and precision of measurements. Potassium levels may be... read more
Carbonic anhydrase inhibitors in patients with respiratory failure and metabolic alkalosis
In patients with respiratory failure and metabolic alkalosis, carbonic anhydrase inhibitor therapy may have favorable effects on blood gas parameters. In mechanically ventilated patients, carbonic anhydrase inhibitor therapy... read more
PPIs do not increase risk for C. difficile infection in ICU
Proton pump inhibitors are not associated with an increased risk for Clostridium difficile infection in ICU patients, according to the results of a retrospective cohort study. PPI use was not associated with a significant... read more
New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections
Only few new molecules have an adequate activity against MDR gram-negative pathogens, especially carbapenemase-producer strains. Among these, ceftozolane/tazobactam has been recently approved for clinical use. Other compounds,... read more
A New Combination of Antibiotic and Inhibitor
Intensivists have another antibiotic combination to treat severe infections caused by gram-negative bacteria with the FDA’s approval of Vabomere (meropenem, combined with the beta-lactamase inhibitor called vaborbactam).... read more
GERD Treatment May Reduce Healthcare Visits for Acute Respiratory Infections
Treatment with proton pump inhibitors (PPIs) may help decrease healthcare visits for acute respiratory infections (ARIs) in patients with gastroesophageal reflux disease (GERD). These are the findings of a new study published... read more
Data from clinical registries can ID novel drug interactions
Data mining can be used to discover unknown drug-drug interactions in cardiovascular medicine, according to a study published online Nov. 8 in Circulation: Cardiovascular Quality and Outcomes.... read more
Cellular Mechanisms of Prevention of Ischemia-Reperfusion Injury
Ischemic preconditioning is the phenomenon whereby brief periods of sublethal ischemia protect against a subsequent, more prolonged, ischemic insult.... read more
Impaired recycling of mitochondria in autism?
The new study shows that autophagy is defective in TSC. The scientists further showed that two existing classes of drugs counter the defect: the epilepsy drug carbamazepine, and drugs known as mTOR inhibitors.... read more
HDAC inhibitors show promise against cancer stem cells
A group of researchers, led by scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, has shown that histone deacetylase (HDAC) inhibitors have the potential to eliminate... read more
Bifunctional drug could treat tumors resistant to current mTOR inhibitors
The first known bifunctional inhibitor for the mechanistic target of rapamycin (mTOR) protein was developed to overcome current known mechanisms of tumor resistance to mTOR inhibitors.... read more
